Clinical trial · Interventional
WATCH (Wearable Artificial inTelligence for Cardiac Function and Health Monitoring)
NCT07058064CI-TRIAL-00096595recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find a cost effective cardiovascular (CV) surveillance of cancer survivors over long periods of time to prevent the risk of progression of heart failure (HF) and related morbidity and mortality. Mobile device-based artificial intelligence (AI)-electrocardiogram (ECG) can reliably detect cardiac dysfunction in lymphoma and sarcoma survivors and smart watch based surveillance for cardiotoxicity is feasible and reliable.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
Interventions
Interventions (9)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 6 minute walk test | Other | — | UNRESOLVED |
| Apple Watch | Other | — | UNRESOLVED |
| Biospecimen collection | Procedure | — | UNRESOLVED |
| Cardio-pulmonary exercise test | Other | — | UNRESOLVED |
| Echocardiogram | Procedure | — | UNRESOLVED |
| Electrocardiogram | Procedure | — | UNRESOLVED |
| Grip strength test | Other | — | UNRESOLVED |
| LVEF echocardiogram | Procedure | — | UNRESOLVED |
| Questionnaires | Other |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Cross-sectional Arm
- description
- Lymphoma and sarcoma cancer survivors will be seen at one time point, 1 year after completion of anthracycline-based therapy.
- interventionNames
- Procedure: Electrocardiogram
- Procedure: Echocardiogram
- Procedure: LVEF echocardiogram
- Procedure: Biospecimen collection
- Other: Questionnaires
- type
- EXPERIMENTAL
- label
- Longitudinal Arm
- description
- Lymphoma and sarcoma cancer survivors will be seen before the start of anthracycline-based therapy and followed every three months up to 1 year after completion of therapy. Longitudinal participants will have the option of recording ECG and cardio fitness data through an Apple Watch from before up to 1 year post anthracycline treatment.
- interventionNames
- Procedure: Electrocardiogram
- Procedure: Echocardiogram
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ability to understand study procedures and being willing to comply with them for the entire study length * diagnosis of lymphoma or sarcoma with new start or 1 year after completion of anthracycline therapy Exclusion Criteria: * LVEF \<50% at baseline, or prior confirmed history of heart failure, persistent atrial fibrillation, left bundle branch block, or paced rhythm * Unwilling or unable to give written informed consent * Participants who have opted out of the Minnesota Research Authorization
References
Publications (0)
Data not yet available
No reference posted for this study.